3Semana·

Cadeler

Far too cheap in my opinion

07.05

CAD

Cadeler

Compró 2298 a 4,362 €

10.023,88 €

11 Comentarios

Tenbagger2024@Tenbagger2024

3Semana

Not so favorable when looking at the P/E ratio.
Really cheap when looking at the P/E ratio. A P/E ratio of less than 10, with triple-digit earnings growth, would be rewarded with a decent performance in the tech sector.
I'm surprised how little Cadeler is being played by the stock market
The company is now growing with seven wind turbine installation vessels.
I hope for your sake that the stock market will soon recognize the potential
But I think it will take patience

•

Jonas@Leipziger_Jung

3Semana

@Tenbagger2024 Yes, I think so too. I have patience haha

•

Jonas@Leipziger_Jung

3Semana

By the way @Kundenservice the key figures are wrong

••

N@Khlmysee

1Semana

If Cadeler were to pay out dividends in the future (which does not seem unrealistic given the growth expectations), reclaiming the pro rata withholding tax would of course be annoying.

••

Jonas@Leipziger_Jung

1Semana

@Khlmysee Yes, but I'm not a dividend investor. I think if they paid a dividend, that would be the sign for me to get out.

••

N@Khlmysee

1Semana

@Leipziger_Jung Yes, that's understandable. I'm thinking about getting in because of the dividends and growth prospects, but I have little or no desire for paperwork. 😅

••

Jonas@Leipziger_Jung

1Semana

@Khlmysee If they announce a dividend, you can consider going out again. You would know in advance. It could be years before then. The growth rates are just super strong, especially at the current valuation. According to the efficient market theory, such "market inefficiency" shouldn't even exist 😂

••

N@Khlmysee

1Semana

@Leipziger_Jung do some research on $TMC and the current decrees under Trump. It's about the exploitation of rare earths in the sea - manganese nodules that are to be "harvested" from the seabed. I think that might "strike a chord" with you.

••

Jonas@Leipziger_Jung

1Semana

@Khlmysee No, unfortunately not :D. Commodity exploration and mining companies are always too tricky for me.

••

N@Khlmysee

1Semana

@Leipziger_Jung ok 😅 I think the company is a bit different from conventional exploration companies, but I understand your position. 😊

Do you have anything else exciting?

••

Jonas@Leipziger_Jung

1Semana

@Khlmysee Oh, heaps of them. Besides Cadeler, I also find High Tide exciting as one of the few profitable cannabis companies in Canada. On the one hand, they are super-cheaply valued, have years of growth and, above all, improving margins ahead of them in Canada and are now planning to enter the fast-growing European cannabis markets. First and foremost, they want to expand into Germany, where I expect an announcement from management in the next few weeks. For me a 10x candidate in the next 5 years.

Then next up is Kaspi. High earnings yield and that combined with good return on capital. Expansion into the fast-growing Turkish market because they have slowly eaten up Kazakhstan and built up a quasi-monopoly. They also pay a decent dividend and are growing nicely (only this year they have cut the dividend because they need money for the Turkish expansion). I think that from this level a 5x in the next 5 years is possible and that with a nice dividend as I said.

And then as a play on the next few decades, I find Crispr Therapeutics extremely interesting. Simply because, in my opinion, this is the future of medicine and our species. What's more, Crispr Therapeutics is ahead of its competitors because it already has the first approved treatment for sickle cell anemia (one treatment costs 2.2 million US dollars). There are many exciting candidates in the pipeline that will come in the next few years. In addition, they hold 2 billion US dollars in cash and the company is valued at just over 3 billion, with sales now picking up and increasing profitability due to their casgevy against sickle cell anemia.
However, the first quarters have been disappointing in terms of demand so far, so I want to see how things develop. I'm also bothered by the "once and done" principle from an investor's point of view. I mean, for the patients it's a blessing --> one treatment and you're cured, but from an investor's point of view, they reduce their own TAM with every patient they treat and demonetize themselves bit by bit :D

••